Lv31
310 积分 2024-09-12 加入
The interferon gene signature as a clinically relevant biomarker in autoimmune rheumatic disease
1小时前
已完结
Discovery of Edecesertib (GS-5718): A Potent, Selective Inhibitor of IRAK4
19天前
已完结
IRAK4 degrader in hidradenitis suppurativa and atopic dermatitis: a phase 1 trial
19天前
已完结
PROTACs reach clinical development in inflammatory skin disease
19天前
已完结
Recent advances in interleukin-1 receptor-associated kinase 4 (IRAK4) inhibitors and PROTACs
19天前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
23天前
已完结
Inhibiting the alternative pathway of complement by reducing systemic complement factor B: Randomized, double-blind, placebo-controlled phase 1 studies with Sefaxersen
23天前
已关闭
Safety and efficacy of fenebrutinib in relapsing multiple sclerosis (FENopta): a multicentre, double-blind, randomised, placebo-controlled, phase 2 trial and open-label extension study
25天前
已完结
Safety and efficacy of satralizumab in patients with generalised myasthenia gravis (LUMINESCE): a randomised, double-blind, multicentre, placebo-controlled phase 3 trial
26天前
已完结
VAV1 as a putative therapeutic target in autoimmune and chronic inflammatory diseases
1个月前
已完结
皖公网安备34019202002308
